GetTopicDetailResponse(id=7bab1144686a, topicName=妥拉美替尼, introduction=, content=MEK抑制劑 妥拉美替尼, image=null, comments=0, allHits=824, url=null, type=1, isShow=1, status=1, isAdmin=null, adminId=5395722, adminEncryptionId=cade5395722, adminName=梅斯管理員, createdBy=cade5395722, createdName=梅斯管理員, createdAvatar=, createdTime=Tue May 14 17:59:08 CST 2024, time=2024-05-14, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=490658, tagList=[TagDto(tagId=490658, tagName=妥拉美替尼)], ipAttribution=上海, topicAdmin=0, lengthMark=0)
[GetTopicListResponse(id=2211946, encodeId=055b2211946bc, content=<a href='/topic/show?id=ed70e91027a' target=_blank style='color:#2F92EE;'>#維莫非尼#</a> <a href='/topic/show?id=b85c115938d9' target=_blank style='color:#2F92EE;'>#BRAF V600突變#</a> <a href='/topic/show?id=7bab1144686a' target=_blank style='color:#2F92EE;'>#妥拉美替尼#</a>, objectTitle=EXP HEMATOL ONCOL：妥拉美替尼 (HL-085) 與維莫非尼聯(lián)合治療BRAF V600突變實體瘤的 I 期臨床試驗, objectType=article, longId=830734, objectId=bc5b830e34bc, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240621/1718954446002_92910.png, objectUrl=/article/show_article.do?id=bc5b830e34bc, replyNumber=0, likeNumber=80, createdTime=2024-06-27, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=bc5b830e34bc, moduleTitle=EXP HEMATOL ONCOL：妥拉美替尼 (HL-085) 與維莫非尼聯(lián)合治療BRAF V600突變實體瘤的 I 期臨床試驗, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=bc5b830e34bc)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2204677, encodeId=803c22046e70f, content=<a href='/topic/show?id=c3e91152873' target=_blank style='color:#2F92EE;'>#MEK抑制劑#</a> <a href='/topic/show?id=7bab1144686a' target=_blank style='color:#2F92EE;'>#妥拉美替尼#</a>, objectTitle=大咖談 | MEK抑制劑妥拉美替尼研發(fā)歷程簡介, objectType=article, longId=825524, objectId=a1228255241b, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240514/1715677048620_5579292.png, objectUrl=/article/show_article.do?id=a1228255241b, replyNumber=0, likeNumber=84, createdTime=2024-05-14, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=a1228255241b, moduleTitle=大咖談 | MEK抑制劑妥拉美替尼研發(fā)歷程簡介, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=a1228255241b)], followStatus=false, userIsMember=false, type=null, lengthMark=0)]
梅斯管理員
2024-05-14發(fā)表于上海
